Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 385

1.

The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes.

Mulder SD, Veerhuis R, Blankenstein MA, Nielsen HM.

Exp Neurol. 2012 Jan;233(1):373-9. doi: 10.1016/j.expneurol.2011.11.001.

PMID:
22101005
2.

Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro.

Mulder SD, Nielsen HM, Blankenstein MA, Eikelenboom P, Veerhuis R.

Glia. 2014 Apr;62(4):493-503. doi: 10.1002/glia.22619.

PMID:
24446231
3.

The role of astrocytes in amyloid β-protein toxicity and clearance.

Thal DR.

Exp Neurol. 2012 Jul;236(1):1-5. doi: 10.1016/j.expneurol.2012.04.021.

PMID:
22575598
4.

Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro.

Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P.

Acta Neuropathol. 2003 Feb;105(2):135-44.

PMID:
12536224
5.

IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia.

Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H.

J Immunol. 2008 Nov 1;181(9):6503-13.

6.

GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice.

Tian J, Shi J, Zhang L, Yin J, Hu Q, Xu Y, Sheng S, Wang P, Ren Y, Wang R, Wang Y.

Curr Alzheimer Res. 2009 Apr;6(2):118-31.

PMID:
19355846
7.

Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins.

Nielsen HM, Mulder SD, Beliën JA, Musters RJ, Eikelenboom P, Veerhuis R.

Glia. 2010 Aug;58(10):1235-46. doi: 10.1002/glia.21004.

PMID:
20544859
8.

Leptin inhibits amyloid β-protein degradation through decrease of neprilysin expression in primary cultured astrocytes.

Yamamoto N, Tanida M, Ono Y, Kasahara R, Fujii Y, Ohora K, Suzuki K, Sobue K.

Biochem Biophys Res Commun. 2014 Feb 28;445(1):214-7. doi: 10.1016/j.bbrc.2014.01.168.

PMID:
24508800
9.

Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.

Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM.

Neurobiol Aging. 2005 May;26(5):645-54.

PMID:
15708439
10.

Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β.

Tayler H, Fraser T, Miners JS, Kehoe PG, Love S.

J Alzheimers Dis. 2010;22(4):1363-73. doi: 10.3233/JAD-2010-101368.

PMID:
20930272
11.

Ketamine reduces amyloid β-protein degradation by suppressing neprilysin expression in primary cultured astrocytes.

Yamamoto N, Arima H, Naruse K, Kasahara R, Taniura H, Hirate H, Sugiura T, Suzuki K, Sobue K.

Neurosci Lett. 2013 Jun 17;545:54-8. doi: 10.1016/j.neulet.2013.04.016.

PMID:
23624023
12.

Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology.

Vepsäläinen S, Hiltunen M, Helisalmi S, Wang J, van Groen T, Tanila H, Soininen H.

Neurosci Lett. 2008 Jun 20;438(2):216-20. doi: 10.1016/j.neulet.2008.04.025.

PMID:
18455870
13.

Sevoflurane alters the expression of receptors and enzymes involved in Aβ clearance in rats.

Liu Y, Gao M, Ma L, Zhang L, Pan N.

Acta Anaesthesiol Scand. 2013 Aug;57(7):903-10. doi: 10.1111/aas.12098.

PMID:
23495897
14.

LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes.

Arélin K, Kinoshita A, Whelan CM, Irizarry MC, Rebeck GW, Strickland DK, Hyman BT.

Brain Res Mol Brain Res. 2002 Jul 15;104(1):38-46.

PMID:
12117549
15.

Aβ-degrading enzymes: potential for treatment of Alzheimer disease.

Miners JS, Barua N, Kehoe PG, Gill S, Love S.

J Neuropathol Exp Neurol. 2011 Nov;70(11):944-59. doi: 10.1097/NEN.0b013e3182345e46. Review.

16.

Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease.

Dorfman VB, Pasquini L, Riudavets M, López-Costa JJ, Villegas A, Troncoso JC, Lopera F, Castaño EM, Morelli L.

Neurobiol Aging. 2010 Oct;31(10):1743-57. doi: 10.1016/j.neurobiolaging.2008.09.016.

17.

p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain.

Wang YJ, Wang X, Lu JJ, Li QX, Gao CY, Liu XH, Sun Y, Yang M, Lim Y, Evin G, Zhong JH, Masters C, Zhou XF.

J Neurosci. 2011 Feb 9;31(6):2292-304. doi: 10.1523/JNEUROSCI.2733-10.2011.

18.

Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.

Jha NK, Jha SK, Kumar D, Kejriwal N, Sharma R, Ambasta RK, Kumar P.

J Alzheimers Dis. 2015;48(4):891-917. doi: 10.3233/JAD-150379. Review.

PMID:
26444774
19.

Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.

Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS.

J Neurochem. 2010 Oct;115(1):47-57. doi: 10.1111/j.1471-4159.2010.06899.x.

20.

Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathology.

Zhao Z, Ho L, Wang J, Qin W, Festa ED, Mobbs C, Hof P, Rocher A, Masur S, Haroutunian V, Pasinetti GM.

FASEB J. 2005 Dec;19(14):2081-2.

Items per page

Supplemental Content

Support Center